Avingtrans Plc · LSE:AVG
Avingtrans — Investor Day (April 2026)
38 slides from Avingtrans's investor day presentation, Apr 16, 2026
Slide 1: Capital Markets Day
/% Avingtrans Capital Markets Day Luton, 16 April 2026
Slide 2: Disclaimer
Disclaimer All statements included in this presentation, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates, projections and assumptions, and events beyon d our control, all
Slide 3: Medical & Industrial Imaging Division
Medical & Industrial Imaging Division Avingtrans Medical & Industrial Imaging Division
Slide 4: Our 5-year vision
Our 5-year vision Our 2031 vision revenue is aspirational and for illustrative purposes only. It should not be construed as formal guidance Comprising layered technology platforms with shared magnet and imaging IP and diversified revenue streams + LONG-TERM MEDICAL IMAGING VALUE ENGINE LAYERED X-RAY
Slide 5: Global footprint
Global footprint Although our medical imaging companies were broadly pre-revenue, our four global locations generated £5m revenue in FY2025 + SCIENTIFIC MAGNETICS Tecmag Magnetica Houston Brisbane USA Australia MR and NMR Compact MRI Spectrometers SciMag Adaptix Oxford Oxford & UK Edinburgh Supercon
Slide 6: Orthopedic Imaging
ORTHOPEDIC IMAGING
Slide 7: X-ray extremity imaging – the market gap
X-ray extremity imaging – the market gap 2D X-ray gives a limited view of 3D CT and 3D cone beam give higher our 3D body, but is low dose and quality images, but are high cost, high relatively low cost dose with longer waiting times Portable 3D X-ray using digital tomosynthesis gives CT-like image c
Slide 8: Adaptix: Ortho350 how it works
Adaptix: Ortho350 how it works A series of x-rays are taken at various angles Results displayed as a stack of slices running through the 3D structure Low dose X- ray source firing from a range of positions on a 2D- grid (No external movement.) Tomosynthesis reconstruction of all the projections give
Slide 9: Adaptix: Ortho350
Adaptix: Ortho350 • 3D X-ray that is better, safer, smaller and more affordable • Addresses the limitations of traditional 2D X-ray imaging, while offering a more accessible and cost-effective alternative to full CT scanning • FDA cleared in November 2025 • First US resellers signed in Q1 2026 “We h
Slide 10: Adaptix: Ortho350 US segment mapping
Adaptix: Ortho350 US segment mapping Segment 1 Segment 2 Segment 3 Segment 4 Segment 5 ED hospitals IDNs Ortho Centres Outpatient Imaging Urgent Care Centres with CT/MRI bottlenecks Message: Message: Message: Message: Message: One Ortho350 in ED can free up Network wide utilisation of 3D imaging rev
Slide 11: Adaptix Ortho350 – capacity release assumptions
Adaptix Ortho350 – capacity release assumptions • For an institution with 50 extremity injuries per day, this equals: • 10 referrals (20%) split as Potential to • 8 x 20-minute CT scans (80%) = 160 mins generate • 2 x 45-min MRI scans (20%) = 90 mins • Assuming 80% efficiency, this frees up: >$900,0
Slide 12: Commercial milestones to the end FY 2027
Commercial milestones to the end FY 2027 H2 FY26 H1 FY27 H2 FY27 Clinical 2 KOL sites Up to 4 further KOL sites installed CPT coding validation in-use evidence Up to 6 clinical case studies/white papers Validated capacity release model data Commercial FDA cleared 2 US resellers Trained Up to 3 furth
Slide 13: MRI extremity imaging – the market gap
MRI extremity imaging – the market gap <1T MSK MRI imaging giving lower 3T whole body MRI platforms giving quality images at lower price and high quality images at a high price small footprint and large footprint Compact 3T MSK giving high quality images at one third of the full body cost with a sma
Slide 14: Magnetica Compact MRI (MSK)
Magnetica Compact MRI (MSK) • Engineering compact and light-weight superconducting helium-free 3T Compact MRI systems to bring high-quality imaging close to the patient at point-of-care • Compact design expands the MRI serviceable market into decentralised MSK sites previously constrained by weight,
Slide 15: Magnetica Compact MRI (cont)
Magnetica Compact MRI (cont) • Compact 3T system benefits • Same imaging quality as full body system (3T) • c.25% of full body system weight • c.50% of full body room footprint • Helium-free • No helium gas safety system required • c. 30% of full body fully installed lifetime cost
Slide 16: AIMG Advanced Imaging & Magnetics Group
AIMG Advanced Imaging & Magnetics Group LAYERED TECHNOLOGY REVENUE STREAMS utilising group technology IP in new, high value, emerging markets
Slide 17: Scientific Magnetics
Scientific Magnetics • SciMag designs and manufactures standard and tailor-made bespoke superconducting magnet and cryogenic solutions for academic and industrial-based applications • We are world leaders in designing and manufacturing magnets for quantum computing research, specifically Ion trappin
Slide 18: Scientific Magnetics – new markets
Scientific Magnetics – new markets • Superconducting magnets provide • ultra-stable, extremely homogeneous magnetic fields • near-zero electrical resistance (so no energy loss) • minimal thermal noise • These are precisely the attributes required for quantum computing and as a result, underpin sever
Slide 19: Adaptix NDT (non destructive testing)
Adaptix NDT (non destructive testing) Revolutionizing NDT with 3D X-Ray • Adaptix NDT offers 3D internal visualization at the point of diagnostics earlier in manufacture and through-life with a consistent digital output • Deployable now 3D X-ray for manufacturing and maintenance • Finding faults/rew
Slide 20: Adaptix NDT (cont)
Adaptix NDT (cont) • The aerospace and specialist automotive markets are starting to show encouraging first traction, with the company signing its first material inspection contract at the end of Feb 26 • Highlighting its potentially groundbreaking impact within the $1bn NDT inspection market
Slide 21: Portfolio serviceable addressable market summary
Portfolio serviceable addressable market summary • Combined annual SAM of c.$0.9bn • Extremity 3D X-ray: $221m • Compact MSK MRI: $338m • Quantum magnets: $150m • NDT 3D X-ray: $165m • Revenue vision of c.$150m in 2031 represents a c.17% blended market share of annualised SAM • Through diversified,
Slide 22: 2026 milestones
2026 milestones • Ortho350 • NDT • 6 months of claims data on 76100 from all KOL sites • Material contracts x 3 • Resellers trained and selling in all key states • Aerospace prime x 1 • Capacity release – first US hospital trial signed • SciMag • First US and UK sales • £5m + forward order book • Ma
Slide 23: Message vision in December 2026
Message vision in December 2026 We have validated US orthopaedic commercial traction, de- risked our compact MRI regulatory pathway, secured material contracts in industrial X-ray and quantum magnets, demonstrating the long-term potential and value of the division
Slide 24: Any questions?
Medical & Industrial Imaging Division Any questions?
Slide 25: Advanced Engineering Systems
Advanced Engineering Systems Austen Adams Group COO 16th April 2026
Slide 26: Overview – AES
Overview – AES • 920 Employees • 15 Locations • £160m+ Sales Acquired 2004 Acquired 2019 Acquired 2023 Acquired 2017 Acquired 2018 Acquired 2019 Nuclear containers HVAC Pumps and Nuclear parts and High integrity Super precision Heating and High integrity Motors fabrications doors pumps fabrication C
Slide 27: Equity story - AES
Equity story - AES Mission-critical High barriers to Strong visibility and products in highly Positioned for structural entry and long recurring revenues regulated sectors growth tailwinds qualification cycles • Engineering driven • Multi-year • Mix of long-term • Nuclear: energy security Mix of lon
Slide 28: Diversified end markets - AES
Diversified end markets - AES By region By Industry Oil & Gas, Other, 2% Rest of Industrial & world, Gov. and 4% infrastr., defence, 17% 34% 9% UK, 40% Nuclear, China, 20% 16% Nuclear Resurgence Conventional USA, 26% power, 30% Geographical and sectorial risk mitigated – shift from conventional powe
Slide 29: Market positioning – AES
Market positioning – AES Industrial / Defence Defence Critical National HVAC heating Advanced Fibres Infrastructure and cooling Nuclear deterrent HS2 Large buildings Advanced materials Secure storage Rail tunnels Data Centres for AI Precision pumps Nuclear Submarine High Integrity Doors Booth Haywar
Slide 30: Market positioning – AES Cont. (Energy)
Market positioning – AES Cont. Energy Bridging the gap - keeping the lights on…. Hydrocarbons China is still building coal fired plants New Build Life extension of 140 plants last 2 years existing assets 200 still in build / planning Coal - China Global installed Global Oil & Gas base of 3rd party k
Slide 31: Market positioning – AES Cont. (Nuclear)
Market positioning – AES Cont. Energy Commanding niche positions in attractive growth segments capitalising on the sector transition Nuclear New Build - Fusion – Life extension of Decommission existing mature transformational existing assets of used assets technologies technologies Westinghouse ITER
Slide 32: New Nuclear Landscape - AES
New Nuclear Landscape - AES The new nuclear opportunity is driven by an unprecedented convergence of Big Tech energy demand, aggressive federal de-risking by the US government and a shift toward "economies of scale" production for SMRs New Nuclear – Players USA Players RoW Market demand drivers rapi
Slide 33: TerraPower Natrium Timeline - AES
TerraPower Natrium Timeline - AES 2025 2026 2027 2028 2029 LONG LEAD RAW MATERIAL PURCHASES ROLLING FOR 12 MONTHS DESIGN DEVELOPMENT MATERIAL DELIVERIES MANUFACTURING ASSEMBLY AND TEST OF PROTOTYPE ASSEMBLY AND TEST FULL UNITS This is a long-term program and we are well established Next up - commerc
Slide 34: HT & ESSC Nuclear Pipeline - AES
HT & ESSC Nuclear Pipeline - AES Technology Company Relationship Molten Chloride Fast Reactor (TerraPower) 50% complete with MCRE; DELTA Engineering development underway Natrium Reactor (TerraPower) Design in process; Long lead material procurement underway BWRX-300 Reactor (GE-Hitachi) Supporting G
Slide 35: Track Record– AES
Track Record– AES £m AES Growth 160 • Consistent revenue growth 140 120 100 • Margin resilience 80 15% CAGR 60 • Strong cash generation 40 20 • Disciplined capital management 0 FY22 FY23 FY24 FY25 Revenue AEBITDA Linear (Revenue) Growth > Peers - Senior, Rotork, Morgan, Hunting • Diversified end mar
Slide 36: Growth Strategy– AES
Growth Strategy– AES • Organic growth through capacity and capability expansion AES • Expansion into adjacent regulated market niches • Selective M&A aligned to core competencies • Leveraging existing certifications Pinpoint Invest Exit
Slide 37: Summary – AES
Summary – AES Defensible niche markets Strong growth tailwinds Robust financial performance Clear strategy for value creation
Slide 38: Disclaimer
Disclaimer All statements included in this presentation, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates, projections and assumptions, and events beyon d our control, all